Healthcare Industry News: Lauriad
News Release - July 17, 2006
BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory DepartmentsPARIS--(HSMN NewsFeed)--July 17, 2006--BioAlliance Pharma SA(PARIS: BIO ), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today it has made three key appointments which bring substantial experience to BioAlliance. Laure Lagon becomes General Counsel, Delphine Lucas Regulatory Affairs Manager and Aude Michel Intellectual Property Manager.
"These three experienced appointments will make an important contribution to BioAlliance's international development as the company rolls out its Phase III trial for Loramyc® in the United States," said Dominique Costantini, MD, president and CEO of BioAlliance Pharma. "The new recruits will strengthen the Company's team in these important areas. They will make a valuable contribution to the company's activities and provide their support in legal and HR affairs, as well as support in meeting regulatory obligations for obtaining Loramyc® market authorizations in Europe. Lastly, they will provide intellectual property protection for projects under development."
Mrs. Lagon, 41, General Counsel, is a qualified lawyer in charge of legal affairs, HR and general affairs. She was previously General Manager Legal Department and External Affairs at Panasonic France. Earlier positions were at Aries, AGF and Fidal Paris & International (KPMG law firm). Mrs. Lagon is a qualified lawyer and has a masters degree (Magistere) in business law, tax law and accountancy, from the Business Law Institute of Aix en Provence, as well as a DESS of international business law, and a Legal Company Adviser diploma (DJCE).
Ms Lucas, 34, Regulatory Affairs Manager, was HIV Regulatory Affairs manager for Pfizer, San Diego, and has extensive FDA experience. Previously, she held regulatory affairs positions at Servier and Boehringer-Ingelheim. Ms Lucas obtained a Pharm. D from the University Paris XI and was awarded first prize for the DESS of international development & registration of medicinal products.
Ms Michel, 27, Intellectual Property Manager, was previously head of the patent department at Inserm, France's medical research agency. She holds the European Patent Attorney diploma from European Patent Office as well as a diploma in patents and trademarks from the CEIPI, an international patent research institute in Strasbourg, and a masters in biology and cellular physiology from the University of Orsay (Paris XI).
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The Company is developing three broad product ranges based on the Lauriad® adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.
The Company's most advanced product, the Loramyc® (miconazole Lauriad®) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, BioAlliance filed a request for Marketing Authorisation (MAA) in Europe for this product. Under an IND allowed by the US Food and Drug Administration (FDA), a pivotal Phase III trial of Loramyc® is ongoing in the US for the same indication. A second product, acyclovir Lauriad®, for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 28 April 2006 under the number R. 06-042, which is available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com.
Source: BioAlliance Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.